New Brunswick, NJ – According to filings with the U.S. Securities and Exchange Commission, Ascendia Pharmaceuticals is raising $2,499,945.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Jingjun Huang played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Ascendia Pharmaceuticals
Ascendia is a specialty pharmaceutical company dedicated to developing enhanced formulations of existing drug products, and enabling formulations for pre-clinical and clinical stage drug candidates. Ascendia provides state-of-the-art formulation development services for poorly water soluble molecules, and cGMP manufacture of clinical trial materials. Applying its nano-particle technologies and expertise, Ascendia can rapidly assess the feasibility of a broad array of formulation options in order to improve a drugs bioavailability. Our technologies include nano-emulsions, amorphous solid dispersions, oral controlled release, self-emulsifying drug delivery systems (SEDDs) and production of nano-particles. Ascendia provides development and testing services from pre-formulation through to manufacture of pilot clinical supplies. We execute rapid, comprehensive, and cost-effective programs for our clients. We partner with emerging, discovery-stage pharmaceutical companies to provide early-stage formulations; with generic companies that seek enabling technology fort ANDA development projects; and with specialty pharmaceutical companies that need development of new 505(b)(2) products for clinical testing.

To learn more about Ascendia Pharmaceuticals, visit http://ascendiapharma.com/

Contact:
Jingjun Huang, President and Chief Executive Officer
732-640-0058
j.huang@ascendiapharma.com

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved